Managing risks of TNF inhibitors: an update for the internist.
Tumor necrosis factor (TNF) inhibitors have many beneficial effects, but they also pose infrequent but significant risks, including serious infection and malignancy. These risks can be minimized by judicious patient selection, appropriate screening, careful monitoring during treatment, and close communication between primary care physicians and subspecialists.
Division of Gastroenterology, Hepatology, and Nutrition, Allegheny Health Network, Pittsburgh, PA.
Jennifer
J
Hadam
Elie
E
Aoun
Kofi
K
Clarke
Mary Chester
MC
Wasko
D018501:Antirheumatic Agents / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced; D002318:Cardiovascular Diseases / Q000139:chemically induced; D003711:Demyelinating Diseases / Q000139:chemically induced; D003879:Dermatologic Agents / Q000009:adverse effects*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007239:Infections / Q000139:chemically induced*; D009369:Neoplasms / Q000139:chemically induced*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D018501:Antirheumatic Agents; D003879:Dermatologic Agents; D005765:Gastrointestinal Agents; D014409:Tumor Necrosis Factor-alpha